Nadathur Group

The Nadathur Group manages multi-generational portfolios and invests across traditional and alternative asset classes. It has significant investments in healthcare and biotechnology through its venture arms but does not develop drugs or therapies itself. Its portfolio includes major stakes in companies like Indegene—a leading digital-first commercialization partner for global life sciences companies.

The group’s investment approach spans information technology, hospitality, aerospace, biotechnology, healthcare, education, real estate, arts and more. In the health/life sciences sector specifically it acts as an investor rather than operator.

For example:

• Through its entity "Nadathur Fareast Pte Ltd", it was the largest shareholder of Indegene at IPO with a 23.64% stake. Indegene provides services such as drug development support and clinical trials management for biopharmaceutical clients globally.

• The group also supports scientific research & healthcare philanthropy initiatives.

No direct clinical results or pipeline programs are attributable to the group itself.

Portfolio breadth varies by year; typically less than two new deals per year with focus on high-potential ventures at early stages.

Key portfolio companies include Indegene (life sciences services), Paladion (cybersecurity), Cooptions Technologies (ICT/software), Amagi Media Labs (media tech).